A recent scoping review from the Widening Access to Trials in Care Homes project highlights critical barriers and facilitators to recruiting care home (CH) residents into clinical trials for pharmacological treatments. The review synthesized data from 14,301 records, ultimately including eight articles that spanned various studies conducted in the USA, UK, and France. It emphasizes the significant screen failure rates observed, ranging from 18% to 96%, which underscores the challenges faced in evaluating treatments for this vulnerable population, particularly those with frailty and dementia.

The findings reveal a complex interplay of factors affecting recruitment, including study design, selection criteria, and participant retention strategies. Notably, the review identified logistical and operational barriers, as well as ethical considerations that complicate the inclusion of CH residents in clinical trials. These insights are crucial for understanding the generalizability of trial results and ensuring that pharmacological interventions are tested in populations that closely mirror the patients they are intended to benefit.

The implications of this research are significant for the field of aging biology and longevity science. By addressing the identified barriers, researchers can enhance the inclusivity of clinical trials, ultimately leading to more robust data that informs evidence-based care for CH residents. This shift not only improves the therapeutic landscape for older adults but also accelerates the development timelines for new treatments, ensuring that the unique needs of this demographic are met in future pharmacological research.

Source: academic.oup.com